Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Browse by Research Team

Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Source

Article

Isolation of neoantigen-specific human T cell receptors from different human and murine repertoires.
Grunert, C. and Willimsky, G. and Peuker, C.A. and Rhein, S. and Hansmann, L. and Blankenstein, T. and Blanc, E. and Beule, D. and Keller, U. and Pezzutto, A. and Busse, A.
Cancers 14 (7): 1842. 6 April 2022

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.
Çınar, Ö. and Brzezicha, B. and Grunert, C. and Kloetzel, P.M. and Beier, C. and Peuker, C.A. and Keller, U. and Pezzutto, A. and Busse, A.
Journal for ImmunoTherapy of Cancer 9 (7): e002410. 30 July 2021

Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges.
Herda, S. and Heimann, A. and Obermayer, B. and Ciraolo, E. and Althoff, S. and Ruß, J. and Grunert, C. and Busse, A. and Bullinger, L. and Pezzutto, A. and Blankenstein, T. and Beule, D. and Na, I.K.
International Journal of Cancer 148 (12): 3097-3110. 15 June 2021

Spontaneous non-sustained ventricular tachycardia and premature ventricular contractions and their prognostic relevance in patients with cancer in routine care.
Albrecht, A. and Porthun, J. and Eucker, J. and Coats, A.J.S. and von Haehling, S. and Pezzutto, A. and Karakas, M. and Riess, H. and Keller, U. and Landmesser, U. and Haverkamp, W. and Anker, S.D. and Anker, M.S.
Cancers 13 (10): 2303. 12 May 2021

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
Wulf, G.G. and Altmann, B. and Ziepert, M. and D'Amore, F. and Held, G. and Greil, R. and Tournilhac, O. and Relander, T. and Viardot, A. and Wilhelm, M. and Wilhelm, C. and Pezzutto, A. and Zijlstra, J.M. and Van Den Neste, E. and Lugtenburg, P.J. and Doorduijn, J.K. and van Gelder, M. and van Imhoff, G.W. and Zettl, F. and Braulke, F. and Nickelsen, M. and Glass, B. and Rosenwald, A. and Gaulard, P. and Loeffler, M. and Pfreundschuh, M. and Schmitz, N. and Trümper, L.
Leukemia 35 (1): 143-155. January 2021

High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann, R. and Voskanyan, A. and Lauseker, M. and Pfirrmann, M. and Kalmanti, L. and Rinaldetti, S. and Kohlbrenner, K. and Haferlach, C. and Schlegelberger, B. and Fabarius, A. and Seifarth, W. and Spieß, B. and Wuchter, P. and Krause, S. and Kolb, H.J. and Neubauer, A. and Hossfeld, D.K. and Nerl, C. and Gratwohl, A. and Baerlocher, G.M. and Burchert, A. and Brümmendorf, T.H. and Hasford, J. and Hochhaus, A. and Saußele, S. and Baccarani, M.
Leukemia 34 (8): 2074-2086. August 2020

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz, S. and O'Connor, O.A. and Pro, B. and Illidge, T. and Fanale, M. and Advani, R. and Bartlett, N.L. and Christensen, J.H. and Morschhauser, F. and Domingo-Domenech, E. and Rossi, G. and Kim, W.S. and Feldman, T. and Lennard, A. and Belada, D. and Illés, A. and Tobinai, K. and Tsukasaki, K. and Yeh, S.P. and Shustov, A. and Hüttmann, A. and Savage, K.J. and Yuen, S. and Iyer, S. and Zinzani, P.L. and Hua, Z. and Little, M. and Rao, S. and Woolery, J. and Manley, T. and Trümper, L.
Lancet 393 (10168): 229-240. 19 January 2019

Confocal endomicroscopy in diagnosis of intestinal chronic graft-versus-host disease.
Rieger, K. and Günther, U. and Erben, U. and Kühl, A. and Loddenkemper, C. and Pezzutto, A. and Siegmund, B. and Bojarski, C.
Hematological Oncology 36 (1): 291-298. February 2018

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Hehlmann, R. and Lauseker, M. and Saußele, S. and Pfirrmann, M. and Krause, S. and Kolb, H.J. and Neubauer, A. and Hossfeld, D.K. and Nerl, C. and Gratwohl, A. and Baerlocher, G.M. and Heim, D. and Brümmendorf, T.H. and Fabarius, A. and Haferlach, C. and Schlegelberger, B. and Müller, M.C. and Jeromin, S. and Proetel, U. and Kohlbrenner, K. and Voskanyan, A. and Rinaldetti, S. and Seifarth, W. and Spieß, B. and Balleisen, L. and Goebeler, M.C. and Hänel, M. and Ho, A. and Dengler, J. and Falge, C. and Kanz, L. and Kremers, S. and Burchert, A. and Kneba, M. and Stegelmann, F. and Köhne, C.A. and Lindemann, H.W. and Waller, C.F. and Pfreundschuh, M. and Spiekermann, K. and Berdel, W.E. and Müller, L. and Edinger, M. and Mayer, J. and Beelen, D.W. and Bentz, M. and Link, H. and Hertenstein, B. and Fuchs, R. and Wernli, M. and Schlegel, F. and Schlag, R. and de Wit, M. and Trümper, L. and Hebart, H. and Hahn, M. and Thomalla, J. and Scheid, C. and Schafhausen, P. and Verbeek, W. and Eckart, M.J. and Gassmann, W. and Pezzutto, A. and Schenk, M. and Brossart, P. and Geer, T. and Bildat, S. and Schäfer, E. and Hochhaus, A. and Hasford, J.
Leukemia 31 (11): 2398-2406. November 2017

Immunomodulatory molecules in renal cell cancer: CD80 and CD86 are expressed on tumor cells.
Flörcken, A. and Johannsen, M. and Nguyen-Hoai, T. and Gerhardt, A. and Miller, K. and Dörken, B. and Pezzutto, A. and Westermann, J. and Jöhrens, K.
International Journal of Clinical and Experimental Pathology 10 (2): 1443-1454. 15 February 2017

Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223.
Berenstein, R. and Nogai, A. and Waechter, M. and Blau, O. and Kuehnel, A. and Schmidt-Hieber, M. and Kunitz, A. and Pezzutto, A. and Dörken, B. and Blau, I.W.
Molecular Carcinogenesis 55 (12): 1927-1939. December 2016

Splenic marginal zone granulocytes acquire an accentuated neutrophil B cell-helper phenotype in chronic lymphocytic leukemia.
Gätjen, M. and Brand, F. and Grau, M. and Gerlach, K. and Kettritz, R. and Westermann, J. and Anagnostopoulos, I. and Lenz, P. and Lenz, G. and Höpken, U.E. and Rehm, A.
Cancer Research 76 (18): 5253-5265. 15 September 2016

CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.
Nguyen-Hoai, T. and Pham-Duc, M. and Gries, M. and Dörken, B. and Pezzutto, A. and Westermann, J.
Cancer Gene Therapy 23 (6): 162-167. June 2016

Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma.
Korfel, A. and Schlegel, U. and Herrlinger, U. and Dreyling, M. and Schmidt, C. and von Baumgarten, L. and Pezzutto, A. and Grobosch, T. and Kebir, S. and Thiel, E. and Martus, P. and Kiewe, P.
Journal of Clinical Oncology 34 (15): 1757-1763. 20 May 2016

DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.
Floercken, A. and Kopp, J. and Kölsch, U. and Meisel, C. and Dörken, B. and Pezzutto, A. and Westermann, J.
Human Vaccines & Immunotherapeutics 12 (5): 1117-1123. 3 May 2016

Myeloid-derived suppressor cells in human peripheral blood: optimized quantification in healthy donors and patients with metastatic renal cell carcinoma.
Flörcken, A. and Takvorian, A. and Singh, A. and Gerhardt, A. and Ostendorf, B.N. and Dörken, B. and Pezzutto, A. and Westermann, J.
Immunology Letters 168 (2): 260-267. December 2015

Apoptosis-susceptibility prolongs the lack of memory B cells in acute leukemic patients after allogeneic hematopoietic stem cell transplantation.
Mensen, A. and Oh, Y. and Becker, S.C. and Hemmati, P.G. and Jehn, C. and Westermann, J. and Szyska, M. and Göldner, H. and Dörken, B. and Scheibenbogen, C. and Arnold, R. and Na, I.K.
Biology of Blood and Marrow Transplantation 21 (11): 1895-1906. November 2015

Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia.
Schneider, T. and Flörcken, A. and Singh, A. and Türkmen, S. and Burmeister, T. and Anagnostopoulos, I. and Pezzutto, A. and Dörken, B. and Westermann, J.
Annals of Hematology 94 (8): 1337-1345. August 2015

Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
Oden, F. and Marino, S.F. and Brand, J. and Scheu, S. and Kriegel, C. and Olal, D. and Takvorian, A. and Westermann, J. and Yilmaz, B. and Hinz, M. and Daumke, O. and Höpken, U.E. and Müller, G. and Lipp, M.
Molecular Oncology 9 (7): 1348-1358. August 2015

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML-Study IV.
Saussele, S. and Krauss, M.P. and Hehlmann, R. and Lauseker, M. and Proetel, U. and Kalmanti, L. and Hanfstein, B. and Fabarius, A. and Kraemer, D. and Berdel, W.E. and Bentz, M. and Staib, P. and de Wit, M. and Wernli, M. and Zettl, F. and Hebart, H.F. and Hahn, M. and Heymanns, J. and Schmidt-Wolf, I. and Schmitz, N. and Eckart, M.J. and Gassmann, W. and Bartholomaeus, A. and Pezzutto, A. and Oppliger Leibundgut, E. and Heim, D. and Krause, S.W. and Burchert, A. and Hofmann, W.K. and Hasford, J. and Hochhaus, A. and Pfirrmann, M. and Müller, M.C.
Blood 126 (1): 42-49. 2 July 2015

Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.
Kaeda, J. and Ringel, F. and Oberender, C. and Mills, K. and Quintarelli, C. and Pane, F. and Koschmieder, S. and Slany, R. and Schwarzer, R. and Saglio, G. and Hemmati, P. and van Lessen, A. and Amini, L. and Greese, M. and Vagge, E. and Burmeister, T. and Serra, A. and Carson, A. and Schwarz, M. and Westermann, J. and Jundt, F. and Doerken, B. and le Coutre, P.
Leukemia & Lymphoma 56 (7): 2105-2113. July 2015

Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
Lerch, K. and Meyer, A.H. and Stroux, A. and Hirt, C. and Keller, U. and Viardot, A. and Marks, R. and Schreiber, S. and Pezzutto, A. and Scholz, C.W.
Annals of Hematology 94 (6): 981-988. June 2015

Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
Berenstein, R. and Blau, I.W. and Suckert, N. and Baldus, C. and Pezzutto, A. and Dörken, B. and Blau, O.
Journal of Experimental & Clinical Cancer Research 34 (1): 55. 22 May 2015

Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB.
Flörcken, A. and Grau, M. and Wolf, A. and Weilemann, A. and Kopp, J. and Dörken, B. and Blankenstein, T. and Pezzutto, A. and Lenz, P. and Lenz, G. and Westermann, J.
International Journal of Cancer 136 (8): 1814-1826. 15 April 2015

Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.
Berenstein, R. and Blau, O. and Nogai, A. and Waechter, M. and Slonova, E. and Schmidt-Hieber, M. and Kunitz, A. and Pezzutto, A. and Doerken, B. and Blau, I.W.
BMC Cancer 15 (1): 68. 18 February 2015

BCR-ABL1 acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment.
Neuendorff, N.R. and Schwarz, M. and Hemmati, P. and Tuerkmen, S. and Bommer, C. and Burmeister, T. and Doerken, B. and le Coutre, P. and Arnold, R. and Westermann, J.
Acta Haematologica 133 (2): 237-241. 2015

Gene gun Her2/neu DNA vaccination: evaluation of vaccine efficacy in a syngeneic Her2/neu mouse tumor model.
Nguyen-Hoai, T. and Pezzutto, A. and Westermann, J.
Methods in Molecular Biology 1317 : 17-37. 2015

Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B cell activation and proliferation.
Heinig, K. and Gätjen, M. and Grau, M. and Stache, V. and Anagnostopoulos, I. and Gerlach, K. and Niesner, R.A. and Cseresnyes, Z. and Hauser, A.E. and Lenz, P. and Hehlgans, T. and Brink, R. and Westermann, J. and Dörken, B. and Lipp, M. and Lenz, G. and Rehm, A. and Höpken, U.E.
Cancer Discovery 4 : 1448-1465. December 2014

Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT.
Mensen, A. and Jöhrens, K. and Anagnostopoulos, I. and Demski, S. and Oey, M. and Stroux, A. and Hemmati, P. and Westermann, J. and Blau, O. and Wittenbecher, F. and Movassaghi, K. and Szyska, M. and Thomas, S. and Dörken, B. and Scheibenbogen, C. and Arnold, R. and Na, I.K.
Blood 124 (6): 963-972. 7 August 2014

Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humans.
Ceko, M. and Milenkovic, N. and Le Coutre, P. and Westermann, J. and Lewin, G.R.
Pain 155 (7): 1222-1228. July 2014

R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma.
Kreher, S. and Lammer, F. and Augustin, D. and Pezzutto, A. and Baldus, C.D.
European Journal of Haematology 93 (1): 70-76. July 2014

Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer.
Jehn, C.F. and Böning, L. and Kröning, H. and Pezzutto, A. and Lüftner, D.
European Journal of Cancer 50 (7): 1269-1275. May 2014

Peripheral blood sCD3(-) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma.
Singh, A. and Schabath, R. and Ratei, R. and Stroux, A. and Klemke, C.D. and Nebe, T. and Flörcken, A. and van Lessen, A. and Anagnostopoulos, I. and Dörken, B. and Ludwig, W.D. and Pezzutto, A. and Westermann, J.
Hematological Oncology 32 (1): 16-21. March 2014

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.
Meyer, A.H. and Stroux, A. and Lerch, K. and Eucker, J. and Eitle, J. and Hohloch, K. and Andrzejak, M. and Possinger, K. and Dörken, B. and Pezzutto, A. and Scholz, C.W.
Annals of Oncology 25 (1): 210-215. January 2014

Improvement of paraneoplastic limbic encephalitis after systemic treatment with rituximab in a patient with B-cell chronic lymphocytic leukemia.
Nogai, H. and Israel-Willner, H. and Zschenderlein, R. and Pezzutto, A.
Case Reports in Hematology 2013 : 958704. 1 August 2013

Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Weikert, S. and Kempkensteffen, C. and Busch, J. and Johannsen, M. and Gruenwald, V. and Zimmermann, K. and Floercken, A. and Westermann, J. and Weinkauf, L. and Miller, K. and Keilholz, U.
World Journal of Urology 31 (4): 805-809. August 2013

Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.
Flörcken, A. and Kopp, J. and van Lessen, A. and Movassaghi, K. and Takvorian, A. and Jöhrens, K. and Möbs, M. and Schönemann, C. and Sawitzki, B. and Egerer, K. and Dörken, B. and Pezzutto, A. and Westermann, J.
Human Vaccines & Immunotherapeutics 9 (7): 1217-1227. 1 June 2013

Anti-leukemia T cells in AML: TNF-α(+) CD8(+) T cells may escape detection and possibly reflect a stage of functional impairment.
Flörcken, A. and van Lessen, A. and Terwey, T.H. and Dörken, B. and Arnold, R. and Pezzutto, A. and Westermann, J.
Human Vaccines & Immunotherapeutics 9 (7): 1200-1204. 1 June 2013

High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.
Pohla, H. and Buchner, A. and Stadlbauer, B. and Frankenberger, B. and Stevanovic, S. and Walter, S. and Frank, R. and Schwachula, T. and Olek, S. and Kopp, J. and Willimsky, G. and Stief, C.G. and Hofstetter, A. and Pezzutto, A. and Blankenstein, T. and Oberneder, R. and Schendel, D.J.
Molecular Medicine 18 : 1499-1508. 8 February 2013

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.
Scholz, C.W. and Pinto, A. and Linkesch, W. and Lindén, O. and Viardot, A. and Keller, U. and Hess, G. and Lastoria, S. and Lerch, K. and Frigeri, F. and Arcamone, M. and Stroux, A. and Frericks, B. and Pott, C. and Pezzutto, A.
Journal of Clinical Oncology 31 (3): 308-313. 20 January 2013

HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: gene gun is superior to jet injector in inducing CTL responses and protective immunity.
Nguyen-Hoai, T. and Kobelt, D. and Hohn, O. and Vu, M.D. and Schlag, P.M. and Doerken, B. and Norley, S. and Lipp, M. and Walther, W. and Pezzutto, A. and Westermann, J.
OncoImmunology 1 (9): 1537-1545. 1 December 2012

CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
Nguyen-Hoai, T. and Hohn, O. and Vu, M.D. and Baldenhofer, G. and Sayed Ahmed, M.S. and Doerken, B. and Norley, S. and Lipp, M. and Pezzutto, A. and Westermann, J.
Cancer Gene Therapy 19 (12): 880-887. December 2012

Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer.
Jehn, C.F. and Flath, B. and Strux, A. and Krebs, M. and Possinger, K. and Pezzutto, A. and Lueftner, D.
Breast Cancer Research and Treatment 136 (3): 789-794. December 2012

Detection of circulating tumor-associated antigen depends on the domains recognized by the monoclonal antibodies used: N-terminal trimmed EpCAM-levels are much higher than untrimmed forms.
Schmetzer, O. and Moldenhauer, G. and Nicolaou, A. and Schlag, P. and Riesenberg, R. and Pezzutto, A.
Immunology Letters 143 (2): 184-192. 30 April 2012

Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
Floercken, A. and Takvorian, A. and Van Lessen, A. and Singh, A. and Hopfenmueller, W. and Doerken, B. and Pezzutto, A. and Westermann, J.
Anti-Cancer Drugs 23 (3): 298-302. March 2012

CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.
Nguyen-Hoai, T. and Baldenhofer, G. and Ahmed, M.S. and Pham-Duc, M. and Gries, M. and Lipp, M. and Doerken, B. and Pezzutto, A. and Westermann, J.
Journal of Gene Medicine 14 (2): 128-137. February 2012

CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
Nguyen-Hoai, T. and Baldenhofer, G. and Sayed Ahmed, M.S. and Pham-Duc, M. and Vu, M.D. and Lipp, M. and Doerken, B. and Pezzutto, A. and Westermann, J.
Cancer Gene Therapy 19 (1): 69-76. January 2012

Sex differences in the drug therapy for oncologic diseases.
Schmetzer, O. and Floercken, A.
Handbook of Experimental Pharmacology 214 (3): 411-442. 2012

Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells.
Waiczies, H. and Lepore, S. and Janitzek, N. and Hagen, U. and Seifert, F. and Ittermann, B. and Purfürst, B. and Pezzutto, A. and Paul, F. and Niendorf, T. and Waiczies, S.
PLoS ONE 6 (7): e21981. 19 July 2011

Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.
Westermann, J. and Floercken, A. and Willimsky, G. and van Lessen, A. and Kopp, J. and Takvorian, A. and Joehrens, K. and Lukowsky, A. and Schoenemann, C. and Sawitzki, B. and Pohla, H. and Frank, R. and Doerken, B. and Schendel, D.J. and Blankenstein, T. and Pezzutto, A.
Gene Therapy 18 (4): 354-363. April 2011

Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma.
Buchner, A. and Pohla, H. and Willimsky, G. and Frankenberger, B. and Frank, R. and Baur-Melnyk, A. and Siebels, M. and Stief, C.G. and Hofstetter, A. and Kopp, J. and Pezzutto, A. and Blankenstein, T. and Oberneder, R. and Schendel, D.J.
Human Gene Therapy 21 (3): 285-297. March 2010

Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.
Westermann, J. and Hecker, A.C. and Floercken, A. and Doerken, B. and Pezzutto, A.
Journal of Immunotherapy 32 (6): 667-675. July 2009

Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.
Weisel, K.C. and Weidmann, E. and Anagnostopoulos, I. and Kanz, L. and Pezzutto, A. and Subklewe, M.
International Journal of Hematology 88 (4): 434-440. November 2008

Succesful long-term monotherapy with rituximab in a chemotherapy-refractory patient with chronic B-CLL: a case report.
Sturm, I. and Oertel, J. and Oertel, S. and Westermann, J. and Pezzutto, A.
Journal of Medical Case Reports 2 (1): 275. 14 August 2008

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Morschhauser, F. and Seymour, J.F. and Kluin-Nelemans, H.C. and Grigg, A. and Wolf, M. and Pfreundschuh, M. and Tilly, H. and Raemaekers, J. and van't Veer, M.B. and Milpied, N. and Cartron, G. and Pezzutto, A. and Spencer, A. and Reyes, F. and Dreyling, M.
Annals of Oncology 19 (2): 247-253. February 2008

Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study.
Hildebrandt, B. and Mueller, C. and Pezzutto, A. and Daniel, P.T. and Doerken, B. and Scholz, C.
BMC Cancer 7 : 185. 3 October 2007

CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity.
Westermann, J. and Nguyen-Hoai, T. and Baldenhofer, G. and Höpken, U.E. and Lipp, M. and Dörken, B. and Pezzutto, A.
Cancer Gene Therapy 14 (6): 523-532. June 2007

Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann, J. and Kopp, J. and van Lessen, A. and Hecker, A.C. and Baskaynak, G. and le Coutre, P. and Doehner, K. and Doehner, H. and Doerken, B. and Pezzutto, A.
British Journal of Haematology 137 (4): 297-306. May 2007

Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Sebelin-Wulf, K. and Nguyen, T.D. and Oertel, S. and Papp-Vary, M. and Trappe, R. and Schulzki, A. and Pezzutto, A. and Riess, H. and Subklewe, M.
Transplant Immunology 17 (3): 203-210. April 2007

Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Subklewe, M. and Sebelin-Wulf, K. and Beier, C. and Lietz, A. and Mathas, S. and Doerken, B. and Pezzutto, A.
Human Immunology 68 (3): 147-155. March 2007

1H, 15N and 13C assignments of the cysteine protease inhibitor Chagasin from Trypanosoma cruzi.
Aido-Machado, R. and Salmon, D. and Diehl, A. and Leidert, M. and Schmetzer, O. and de Lima, A.P.C.A. and Scharfstein, J. and Oschkinat, H. and Pires, J.R.
Journal of Biomolecular NMR 36 (Suppl) (1): 30. December 2006

Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.
Subklewe, M. and Marquis, R. and Choquet, S. and Leblond, V. and Garnier, J.L. and Hetzer, R. and Swinnen, L.J. and Oertel, S. and Papp-Vary, M. and Gonzalez-Barca, E. and Hepkema, B.G. and Schoenemann, C. and May, J. and Pezzutto, A. and Riess, H.
Transplantation 82 (8): 1093-1100. 27 October 2006

Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients.
Sebelin, K. and Schulzki, A. and Kloetzel, P.M. and Doerken, B. and Pezzutto, A. and Subklewe, M.
Transplantation 82 (6): 779-787. 27 September 2006

Long-lasting remission of pulmonary metastases of renal cell cancer under IFN-beta therapy in a patient with multiple sclerosis.
Floercken, A. and Denecke, T. and Kretzschmar, A. and Gollasch, H. and Reich, G. and Westermann, J.
Onkologie 29 : 382-384. September 2006

Solution structure and backbone dynamics of the Trypanosoma cruzi cysteine protease inhibitor chagasin.
Salmon, D. and Aido-Machado, R. and Diehl, A. and Leidert, M. and Schmetzer, O. and de Lima, A.P. and Scharfstein, J. and Oschkinat, H. and Pires, J.R.
Journal of Molecular Biology 357 (5): 1511-1521. 14 April 2006

Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia.
Westermann, J. and Lessen, A. and Schlimper, C. and Baskaynak, G. and Coutre, P. and Doerken, B. and Pezzutto, A.
British Journal of Haematology 132 : 32-35. January 2006

CD52 is not a promising immunotherapy target for most patients with multiple myeloma.
Westermann, J. and Maschmeyer, G. and Lessen, A. and Doerken, B. and Pezzutto, A.
International Journal of Hematology 82 : 248-250. 1 October 2005

Non-genotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.
Stuehmer, T. and Chatterjee, M. and Hildebrandt, M. and Herrmann, P. and Gollasch, H. and Gerecke, C. and Theurich, S. and Cigliano, L. and Manz, R.A. and Daniel, P.T. and Bommert, K. and Vassilev, L.T. and Bargou, R.C.
Blood 106 : 3609-3617. 4 August 2005

Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.
Frankenberger, B. and Regn, S. and Geiger, C. and Noessner, E. and Falk, C.S. and Pohla, H. and Javorovic, M. and Silberzahn, T. and Wilde, S. and Buchner, A. and Siebels, M. and Oberneder, R. and Willimsky, G. and Pezzutto, A. and Blankenstein, T. and Schendel, D.J.
World Journal of Urology 23 (3): 166-174. 5 July 2005

Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger, B. and Pohla, H. and Noessner, E. and Willimsky, G. and Papier, B. and Pezzutto, A. and Kopp, J. and Oberneder, R. and Blankenstein, T. and Schendel, D.J.
Clinical Cancer Research 11 : 1733-1742. 1 January 2005

Quality of recombinant protein determines the amount of autoreactivity detected against the tumor-associated epithelial cell adhesion molecule antigen: low frequency of antibodies against the natural protein.
Schmetzer, O. and Moldenhauer, G. and Riesenberg, R. and Pires, J.R. and Schlag, P.M. and Pezzutto, A.
Journal of Immunology 174 (2): 942-952. 1 January 2005

Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
Bienert, M. and Reisinger, I. and Srock, S. and Humplik, B.I. and Reim, C. and Kroessin, T. and Avril, N. and Pezzutto, A. and Munz, D.L.
European Journal of Nuclear Medicine and Molecular Imaging 32 : 1225-1233. 1 January 2005

Trimethoprim-sulfamethoxazole exacerbates posthypoxic action myoclonus in a patient with suspicion of Pneumocystis jiroveci infection.
Jundt, F. and Lempert, T. and Doerken, B. and Pezzutto, A.
Infection 32 (3): 176-178. 1 June 2004

T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia.
Westermann, J. and Schlimper, C. and Richter, G. and Mohm, J. and Doerken, B. and Pezzutto, A.
British Journal of Haematology 125 (2): 213-216. 1 April 2004

Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.
Kim, Y.M. and Mapara, M.Y. and Down, J.D. and Johnson, K.W. and Boisgerault, F. and Akiyama, Y. and Benichou, G. and Pelot, M. and Zhao, G. and Sykes, M.
Blood 103 : 732-739. 15 January 2004

Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization.
Westermann, J. and Nguyen-Hoai, T. and Mollweide, A. and Richter, G. and Schmetzer, O. and Kim, H.J. and Blankenstein, T. and Doerken, B. and Pezzutto, A.
Gene Therapy 11 (13): 1048-1056. 1 January 2004

Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma.
Rubio, M.T. and Kim, Y.M. and Sachs, T. and Mapara, M. and Zhao, G. and Sykes, M.
Blood 102 : 2300-2307. 15 September 2003

Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Schlenk, R.F. and Benner, A. and Hartmann, F. and del Valle, F. and Weber, C. and Pralle, H. and Fischer, J.T. and Gunzer, U. and Pezzutto, A. and Weber, W. and Grimminger, W. and Preiss, J. and Hensel, M. and Froehling, S. and Doehner, K. and Haas, R. and Doehner, H.
Leukemia 17 (8): 1521-1528. 1 August 2003

Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties.
Westermann, J. and Koerner, I.J. and Kopp, J. and Kurz, S. and Zenke, M. and Doerken, B. and Pezzutto, A.
Cancer Immunology Immunotherapy 52 (3): 194-198. March 2003

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann, J. and Reich, G. and Kopp, J. and Haus, U. and Doerken, D. and Pezzutto, A.
Cancer Immunology Immunotherapy 49 : 613-620. 1 January 2001

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells.
Richter, G. and Hayden-Ledbetter, M. and Irgang, M. and Ledbetter, J.A. and Westermann, J. and Koerner, I. and Daemen, K. and Clark, E.A. and Aicher, A. and Pezzutto, A.
Journal of Biological Chemistry 276 (49): 45686-45693. 1 January 2001

Status of activation of circulating vaccine-elicited CD8+ T cells.
Nielsen, M.B. and Monsurro, V. and Migueles, S.A. and Wang, E. and Perez-Diez, A. and Lee, K.H. and Kammula, U. and Rosenberg, S.A. and Marincola, F.M.
Journal of Immunology 165 : 2287-2296. 15 August 2000

Allogeneic vaccination for renal cell carcinoma: development and monitoring.
Pohla, H. and Frankenberger, B. and Stadlbauer, B. and Oberneder, R. and Hofstetter, A. and Willimsky, G. and Pezzutto, A. and Doerken, B. and Blankenstein, T. and Schendel, D.J.
Bone Marrow Transplantation 25 Suppl. 2 (3332): S83-S87. 1 May 2000

Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia.
Westermann, J. and Kopp, J. and Koerner, I. and Richter, G. and Qin, Z. and Blankenstein, T. and Doerken, B. and Pezzutto, A.
Bone Marrow Transplantation 25 Suppl. 2 (3332): S46-S49. 1 May 2000

Characterization of human inducible costimulator ligand expression and function.
Aicher, A. and Hayden-Ledbetter, M. and Brady, W.A. and Pezzutto, A. and Richter, G. and Magaletti, D. and Buckwalter, S. and Ledbetter, J.A. and Clark, E.A.
Journal of Immunology 164 (9): 4689-4696. 1 May 2000

Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
Panelli, M.C. and Riker, A. and Kammula, U. and Wang, E. and Lee, K.H. and Rosenberg, S.A. and Marincola, F.M.
Journal of Immunology 164 : 495-504. 1 January 2000

Differential role for p38 mitogen-activated protein kinase in regulating CD40-induced gene expression in dendritic cells and B cells.
Aicher, A. and Shu, G.L. and Magaletti, D. and Mulvania, T. and Pezzutto, A. and Craxton, A. and Clark, E.A.
Journal of Immunology 163 : 5786-5795. 1 December 1999

CD95/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism.
Daniel, P.T. and Scholz, C. and Essmann, F. and Westermann, J. and Pezzutto, A. and Doerken, B.
Experimental Hematology 27 : 1402-1408. 1 September 1999

Direct and indirect T cell priming by dendritic cell vaccines.
Cayeux, S. and Richter, G. and Becker, C. and Pezzutto, A. and Doerken, B. and Blankenstein, T.
European Journal of Immunology 29 : 225-234. 1 January 1999

Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "Veto" apoptosis of antibody-targeted cytotoxic T cells.
Daniel, P.T. and Kroidl, A. and Kopp, J. and Sturm, I. and Moldenhauer, G. and Doerken, B. and Pezzutto, A.
Blood 92 (12): 4750-4757. 15 December 1998

Loss of laminin and of the laminin receptor integrin subunit � in situ correlates with cytokine induced down regulation of alpha 6 on fibroblast-like synoviocytes from rheumatoid arthritis.
Rinaldi, N. and Barth, T.F. and Weis, D. and Schwarz-Eywill, M. and Pezzutto, A. and Lukoschek, M. and Brocai, D. and Brado, B.
Annals of the Rheumatic Diseases 57 : 559-565. 1 September 1998

Dendritic cells for somatic gene therapy.
Westermann, J. and Aicher, A. and Pezzutto, A.
Recent Results in Cancer Research 144 : 70-77. 1 January 1998

Dendritic cells prevent CD95 mediated T lymphocyte death through costimulatory signals.
Daniel, P.T. and Scholz, C. and Westermann, J. and Doerken, B. and Pezzutto, A.
Advances in Experimental Medicine and Biology 451 : 173-177. 1 January 1998

Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis.
Daniel, P.T. and Kroidl, A. and Cayeux, S. and Scholz, C. and Sturm, I. and Blankenstein, T. and Pezzutto, A. and Doerken, B.
Advances in Experimental Medicine and Biology 451 : 265-276. 1 January 1998

Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation.
Westermann, J. and Aicher, A. and Qin, Z. and Cayeux, S. and Daemen, K. and Blankenstein, T. and Doerken, B. and Pezzutto, A.
Gene Therapy 5 : 264-271. 1 January 1998

Differential expression and functional behaviour of the ഠand ౠintegrin subunits in cytokine stimulated fibroblast-like cells derived from synovial tissue of rheumatoid arthritis and osteoarthritis in vitro.
Rinaldi, N. and Weis, D. and Brado, B. and Schwarz-Eywill, M. and Lukoschek, M. and Pezzutto, A. and Keilholz, U. and Barth, T.F.
Annals of the Rheumatic Diseases 56 : 729-736. 1 December 1997

Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency.
Cayeux, S. and Richter, G. and Becker, C. and Beck, C. and Aicher, A. and Pezzutto, A. and Doerken, B. and Blankenstein, T.
European Journal of Immunology 27 : 1657-1662. 1 January 1997

Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells.
Aicher, A. and Westermann, J. and Cayeux, S. and Willimsky, G. and Daemen, K. and Blankenstein, T. and Uckert, W. and Doerken, B. and Pezzutto, A.
Experimental Hematology 25 : 39-44. 1 January 1997

Book Section

Humoral immunotherapy and the use of monoclonal antibodies.
Daniel, P.T. and Pezzutto, A. and Doerken, B.
In: Textbook of Malignant Haematology. Martin Dunitz Ltd., London, 425-446. 1 January 1999

Book

Taschenatlas der Immunologie : Grundlagen - Labor - Klinik.
Pezzutto, A. and Ulrichs, T. and Burmester, G.R.
Thieme, Stuttgart [u.a.]. ISBN 3-13-115382-2 1 January 2007

Review

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Weber, A.N.R. and Cardona Gloria, Y. and Çınar, Ö. and Reinhardt, H.C. and Pezzutto, A. and Wolz, O.O.
Cancer Immunology Immunotherapy 67 (11): 1797-1807. November 2018

Letter

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part phase Ib/II study.
Rambaldi, A. and Iurlo, A. and Vannucchi, A.M. and Noble, R. and von Bubnoff, N. and Guarini, A. and Martino, B. and Pezzutto, A. and Carli, G. and De Muro, M. and Luciani, S. and McMullin, M.F. and Cambier, N. and Marolleau, J.P. and Mesa, R.A. and Tibes, R. and Pancrazzi, A. and Gesullo, F. and Bettica, P. and Manzoni, S. and Di Tollo, S.
Leukemia 34 (8): 2234-2237. August 2020

Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies.
Çakmak-Görür, N. and Radke, J. and Rhein, S. and Schumann, E. and Willimsky, G. and Heppner, F.L. and Blankenstein, T. and Pezzutto, A.
Leukemia 33 (4): 1039-1043. April 2019

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Dang, N.H. and Ogura, M. and Castaigne, S. and Fayad, L.E. and Jerkeman, M. and Radford, J. and Pezzutto, A. and Bondarenko, I. and Stewart, D.A. and Shnaidman, M. and Sullivan, S. and Vandendries, E. and Tobinai, K. and Ramchandren, R. and Hamlin, P.A. and Giné, E. and Ando, K.
British Journal of Haematology 182 (4): 583-586. August 2018

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL network phase II trial.
Ferrero, S. and Pastore, A. and Scholz, C.W. and Forstpointner, R. and Pezzutto, A. and Bergmann, L. and Truemper, L. and Finke, J. and Keller, U. and Ghione, P. and Passera, R. and Hiddemann, W. and Weigert, O. and Unterhalt, M. and Dreyling, M.
Leukemia 30 (4): 984-987. April 2016

Editorial

Long-term structured follow-up is essential after curative cancer treatment.
Keilholz, U. and Pezzutto, A. and Budach, V. and Eggert, A.
Deutsches Aerzteblatt International 111 (1-2): 1-2. 6 January 2014

This list was generated on Fri Mar 29 02:24:36 2024 CET.
Open Access
MDC Library